Clinical trial NCT04369066: COVID-19 Study of the Serological Response Against the Severe Acute Respiratory Syndrome (SARS) Coronavirus 2 (CoV-2) Virus in 2 Types of Employees, Hospital and Non-hospital, at Institute Curie and Institute Pasteur
Official title: COVID-19 Study of the Serological Response Against the SARS-CoV-2 Virus in 2 Types of Employees, Hospital and Non-hospital, at Institute Curie and Institute Pasteur
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Volunteers From the Institute Curie and Institute Pasteur Staff Who Are Not Showing Active SARS-CoV-2 Infection
Keywords: Adults
Volunteers
Lead sponsor: Institut Curie
Sponsor class: OTHER
First posted: 2020-04-30
Enrollment: 1971
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: This research proposes to study a large healthy population active for the presence of antibodies directed against the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) virus and this over time.

After verification of the inclusion criteria and information by the coordinating investigative doctor, the volunteers sign a written consent. A nurse will take blood samples under safe conditions compatible with the pandemic period and while respecting the protection of the volunteer's personal data.

The blood samples will be taken at 4 times for Institute Curie and Institute Pasteur: T0 (day of inclusion), between 6 weeks and 3 months ,6 months and 12 months post-inclusion.

Each blood sample consists of a collection of 5 mL of blood in a dry tube. The serum samples will be extracted and collected prospectively from the blood samples.

The nasopharyngeal swabs will be performed at 3 times: , between 6 weeks and 3 months, 6 months and 12 months post-inclusion for Institute Curie staff who have had at least one of the following four criteria on the sample or questionnaire carried out at T0:

* have had RT-PCR+
* and/or presence of antibodies at the 95% threshold
* and/or anosmia/ageusia
* and/or digestive syndrome with associated respiratory signs. In case of infection between sampling times, if the volunteer meets one of the four criteria above, a nasopharyngeal swab will be performed during the following visits.

The nasopharyngeal swab shall also be proposed to volunteers not meeting the 4 above listed criteria in order to have a control group (about 100 volunteers) for future statistical analyses.

If the volunteers accept, naso-pharyngeal swab shall be performed between 6 weeks and 3 months, 6 months and 12 months after inclusion.

For volunteers already included at Institute Curie : in case of proved (RT-PCR+ or antigenic +) or very likely (anosmia and/or ageusia, and/or digestive syndrome with associated respiratory signs) between 2 sampling times already planned in the flow chart, blood samples and nasopharyngeal swabs shall be performed.

Those shall be performed if time since last planned sampling(s) has been more than 3 weeks or if time until next sampling(s) is more than 3 weeks.

The blood samplings and nasopharyngeal swabs will be performed at 4 times for Institute Pasteur personnel: at T0 (inclusion day), between 6 weeks and 3 months, at 6 months and 12 months post-inclusion


Eligibility criteria: Inclusion Criteria:

1. Person, adult volunteer outside of any acute infectious episode with SARS-CoV-2\* (see paragraph indication), working at the Institute Curie and able to exercise their professional activity on one of the 3 sites of the Institute Curie: Paris, Orsay or Saint Cloud, or on the Campus of the Institute Pasteur.
2. Person aged 18 or over.
3. Information and consent of the person to the procedures related to the study (cf. information note / consent).

From November 2020, person having presented at least one of the following criteria since January 2020:

* A positive diagnostic test for SARS-COV-2 by PCR on a nasopharyngeal sample or antigenic test,
* A positive SARS-CoV-2 serology,
* An anosmia or / and an ageusia,
* A respiratory infection \*\* associated with digestive signs \*\*

whatever the working methods during confinement \* Subjects who are not showing active SARS-CoV-2 infection are considered volunteers at the time of inclusion: people with no clinical signs \*\* suggestive of SARS-CoV-2 infection at the time of collection or having had an end of symptoms for more than 7 days \[1\].

\*\* fever, fatigue, cough, shortness of breath, difficulty to breath, loss of taste or smell, headache, body aches, conjunctivitis or cold, digestive problems (vomiting, diarrhea), whether or not the signs led to sick leave, treatment and / or hospitalization \[2\].

Exclusion Criteria:

* Declaration by the subject of signs suggestive of Coronavirus Infectious Disease 2019 (COVID-19) infection with SARS-CoV-2 in progress or for which the end of symptoms dates from less than 7 days
* Inability to submit to study monitoring for geographic, social or psychological reasons

Primary outcomes:
measure: Antibodies against the SARS-CoV-2 virus in serum at inclusion
timeFrame: 1 day
measure: Antibodies against the SARS-CoV-2 virus in serum at 1 month
timeFrame: 1 month
measure: Antibodies against the SARS-CoV-2 virus in serum at 3 months
timeFrame: 3 months
measure: Antibodies against the SARS-CoV-2 virus in serum at 6 months
timeFrame: 6 months
measure: Antibodies against the SARS-CoV-2 virus in serum at 12 months
timeFrame: 12 months
Secondary outcomes:
measure: Comparative performance of anti-SARS-CoV-2 antibody detection techniques
timeFrame: 9 months
measure: Prevalence of immune subjects for SARS-CoV-2
timeFrame: 3 months
measure: Nature and quantity of anti-SARS-CoV-2 antibodies
timeFrame: 3 months
measure: Evolution of the different antibodies against the SARS-CoV-2 virus over time.
timeFrame: 6 months
measure: Prevalence of Anti-covid IgA response in the nasal mucosa
timeFrame: 6 months
Other outcomes:
Locations:
city: Paris
country: France
facility: Institut Curie
city: Paris
country: France
facility: Institut Pasteur
Study officials:
affiliation: Institut Curie
name: Pierre Fumoleau, PhD
role: STUDY_DIRECTOR
References: